Share Price, page-9851

It could be. I don't really know if there's 'manipulation' or is it simply a lack of interest. It really seems like the phelan mcdermid syndrome outstanding result was completely overshadowed by the sniff of Daybue peak sales not being as high as expected, and as we know that isn't necessarily the case. We're priced as if it is, though. I think the reality is that Daybue will reach peak sales in North America at a minimum in year 3 (or thereabouts), but reality is the genetic testing will lead to a higher patient population to be treated and those who tolerate the drug after a few months generally seem to stick to it (as evidenced by the Lilac extension trial participants who carried over after the trial finished). This is all completely ignoring RoW sales of course ... oh and the few hundred million dollars in the bank